RESULTS OF MEDICAL THERAPY IN PATIENTS WITH CERVICAL INTRAEPITHELIAL NEOPLASIA I-II (CIN I-II)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the efficiency of medical treatment incorporating promisan in patients with histologically verified cervical intraepithelial neoplasia (CIN) I-II. Subjects and methods. The investigation enrolled 90 reproductive-aged patients who were randomized into three groups. A study group (Group 1) took 2 promisan capsules twice daily during cycle therapy with eubiotics; Group 2 patients underwent radiowave surgery; Group 3 was followed up (a control group). The therapy lasted 12 months. Results. The findings of the clinical trial support the efficiency of promisan therapy. The therapeutic efficiency is proven by the results of cytological monitoring, colposcopy, and polymerase chain reaction. The trial shows that the efficiency of this treatment option can be most adequately evaluated following 12-month therapy. Conclusion. The current treatment policy for CIN I-II in reproductive-aged patients at Stage 1 should be directed at medical treatment incorporating promisan as an effective multitarget agent and at normalization of vaginal biocenosis.

Full Text

Restricted Access

About the authors

Lev A. Ashrafyan

Russian X-ray Radiology Research Center, Ministry of Health of Russia

Email: levaa2004@yahoo.com
Corresponding Member of the Russian Academy of Sciences, Professor, MD, director of early carcinogenesis, prevention, diagnosis and combined treatment of cancer of the female reproductive organs Moscow 117997, Profsoyuznaya str. 86, Russia

Vsevolod I. Kiselev

Institute of Biomedical Problems, People's Friendship University of Russia

Email: vkis10@mail.ru
Corresponding Member of the Russian Academy of Sciences, Professor, PhD, Deputy Director of Institute of Biomedical Problems Moscow 115093, Podolsk sh. 8/5, Russia

Olga Ivanovna Aleshikova

Russian X-ray Radiology Research Center, Ministry of Health of Russia

Email: olga.aleshikova@gmail.com
PhD, Senior Scientist Laboratory early carcinogenesis, prevention, diagnosis and combined treatment of cancer of the female reproductive organs Moscow 117997, Profsoyuznaya str. 86, Russia

Yulia Vladimirovna Ponomareva

Medical Center, Central Bank of the Russian Federation

Email: juliyapon@mail.ru
MD, head of the gynecological department Moscow 117593, Sevastopol Ave. 66, Russia

Igor Nikolaevich Kuznetsov

IlmixGroup

PhD, General Director Moscow 121248, Kutuzov Ave, Russia

Sophiko Levanovna Vashakmadze

Russian X-ray Radiology Research Center, Ministry of Health of Russia

Email: v.sofia.l@gmail.com
graduate student of the department of early carcinogenesis, prevention, diagnosis and combined treatment of cancer of the female reproductive organs Moscow 117997, Profsoyuznaya str. 86, Russia

References

  1. Cancers of the female reproductive tract. In: Stewart B.W., Kleihues P., eds. World Cancer Report. Lyon: IARC Press; 2003: 215-22.
  2. Holowaty P., Miller A.B., Rohan T., To T. Natural history of dysplasia of the uterine cervix. J. Natl. Cancer Inst. 1999; 91(3): 252-8.
  3. Сухих Г.Т., Прилепская В.Н., ред. Профилактика рака шейки матки. Руководство для врачей. 3-е изд. М.: МЕДпресс-информ; 2012. 192с. [Sukhikh G.T., Prilepskaya V.N., eds. Prevention of cervical cancer. Guide for physicians. 3rd ed. Moscow: MEDpress-Inform; 2012 192p. (in Russian)]
  4. Fiedler M., Müller-Holzner E., ViertlerH.P., Widschwendter A., Laich A., Pfister G. et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. FASEB J. 2004; 18(10): 1120-22.
  5. Ressler S., Scheiden R., Dreier K., Laich A., Müller-Holzner E., Pircher H. et al. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin. Cancer Res. 2007; 13(23): 7067-72.
  6. Le Buanec H., D’Anna R., Lachgar A., Zagury J.F., Bernard J., Ittelé D. et al. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed. Pharmacother. 1999; 53(9): 424-31.
  7. Аганезова Н.В. Влияние внутривлагалищной гормональной контрацепции на биоценоз влагалища и слизистую оболочку шейки матки. В кн.: Прилепская В.Н., ред. Патология шейки матки и генитальные инфекции. М.: МЕДпресс-информ; 2008: 136-41
  8. Аполихина И.А., Денисова Е.Д., Ворожцов Г.Н., Кузьмин С.Г. Лечебные и профилактические аспекты папилломавирусной инфекции гениталий. Эффективная фармакотерапия. Акушерство и гинекология. 2009; 1: 26-30
  9. Бауэр Г. Цветной атлас по кольпоскопии. Пер. с нем. М.: ГЭОТАР-Медиа; 2010. 384с
  10. Fang M., Chen D., Yang C.S. Dietary polyphenols may affect DNA methylation. J. Nutr. 2007; 137(1, Suppl.): 223S-8S.
  11. López-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000; 19(40): 4611-20.
  12. Katki H.A., Schiffman M., Castle P.E., Fetterman B., Poitras N.E., Lorey T. et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J. Low. Genit. Tract. Dis. 2013;17(5, Suppl. 1): S78-84.
  13. Moscicki A. CIN management guidelines in adolescents and young women. In: Abstracts the International papillomavirus society symposium. April 13-14 2007. Warsaw; 2007: 17
  14. Aggarwal B.B., Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005; 4(9): 1201-15.
  15. Du G.J., Zhang Z., Wen X.D., Yu C., Calway T., Yuan C.S., Wang C.Z. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012; 4(11): 1679-91.
  16. Bell M.C., Crowley-Nowick P., Bradlow H.L., Sepkovic D.W., Schmidt-Grimminger D., Howell P. et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol. Oncol. 2000; 78(2): 123-9.
  17. Ahn W.S., Yoo J., Huh S.W., Kim C.K., Lee J.M., Namkoong S.E. et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. 2003; 12(5): 383-90.
  18. Сидорова И.С., Унанян А.Л., Киселев В.И., Залетаев Д.В., Евтина И.П. Прогнозирование и профилактика онкотрансформации шейки матки с учетом метилирования генов-супрессоров опухолевого роста. Эффективная фармакотерапия. 2011; 1: 58-61.
  19. Chen D.Z., Qi M., Auborn K.J., Carter T.H. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. J. Nutr. 2001; 131(12): 3294-302.
  20. Chinni S.R., Li Y., Upadhyay S., Koppolu P.K., Sarkar F.H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 2001; 20(23): 2927-36
  21. Fassina G., Venè R., Morini M., Minghelli S., Benelli R., Noonan D.M., Albini A. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by Epigallocatechin-3-Gallate. Clin. Cancer Res. 2004; 10(14): 4865-73.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media